Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
المؤلفون المشاركون
Wang, Lan
Liu, Jinming
Gong, Su-Gang
Pudasaini, Bigyan
Yuan, Ping
Jiang, Rong
Zhao, Qin-Hua
He, Jing
Zhang, Rui
Wu, Wen-hui
Zhou, Cai-cun
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-04-11
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH).
However, there is little information about the transition strategy between these two ETRAs.
We aimed to evaluate the safety and efficacy from ambrisentan to bosentan.
Methods: Twenty PAH patients were enrolled into the single-center, open-labelled prospective study.
Echocardiogram, WHO functional class (WHO-FC), 6-minute walking distance (6MWD), right heart catheterization, and hemotology were collected.
After receiving oral 5 mg ambrisentan daily initially for one year, the patients were divided into two arms: eight patients switched to bosentan, while the remaining 12 patients continued ambrisentan.
Characteristics at baseline, 1-and 2-year follow-up points were compared.
Results: There were no significant differences in echocardiogram, WHO-FC, hemodynamics, demographics and liver function at baseline, 1-and 2-year points in both arms.
6MWD in bosentan group was significantly shorter at baseline.
But there were no significant differences of 6MWD at 1- and 2-year points.
Conclusions: It is safe for stable PAH patients to transition from ambrisentan to bosentan without hemodynamic or hematologic deterioration.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Gong, Su-Gang& Wang, Lan& Pudasaini, Bigyan& Yuan, Ping& Jiang, Rong& Zhao, Qin-Hua…[et al.]. 2018. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. Canadian Respiratory Journal،Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1151949
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Gong, Su-Gang…[et al.]. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. Canadian Respiratory Journal No. 2018 (2018), pp.1-5.
https://search.emarefa.net/detail/BIM-1151949
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Gong, Su-Gang& Wang, Lan& Pudasaini, Bigyan& Yuan, Ping& Jiang, Rong& Zhao, Qin-Hua…[et al.]. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. Canadian Respiratory Journal. 2018. Vol. 2018, no. 2018, pp.1-5.
https://search.emarefa.net/detail/BIM-1151949
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1151949
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر